
LaÃ⁻la-AÃ⁻cha Hanafi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10942849/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS ONE, 2021, 16, e0261987. | 2.5 | 5 |
| 2 | Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications, 2020, 11, 219. | 12.8 | 167 |
| 3 | Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery, 2017, 7, 1404-1419. | 9.4 | 945 |
| 4 | Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood, 2017, 130, 2295-2306. | 1.4 | 774 |
| 5 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib. Journal of Clinical Oncology, 2017, 35, 3010-3020. | 1.6 | 568 |
| 6 | CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138. | 8.2 | 1,657 |
| 7 | Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine, 2016, 8, 355ra116. | 12.4 | 832 |
| 8 | CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 56-56. | 1.4 | 11 |
| 9 | Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells Journal of Clinical Oncology, 2016, 34, 102-102. | 1.6 | 20 |
| 10 | Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism. PLoS ONE, 2014, 9, e99211. | 2.5 | 23 |
| 11 | A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells. Proteomics, 2013, 13, 1108-1120. | 2.2 | 91 |
| 12 | Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. Clinical Cancer Research, 2011, 17, 6985-6991. | 7.0 | 343 |
| 13 | IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Molecular Immunology, 2011, 49, 253-259. | 2.2 | 31 |
| 14 | Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine, 2010, 28, 5617-5626. | 3.8 | 21 |
| 15 | Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance. Journal of Immunology, 2009, 183, 7752-7760. | 0.8 | 47 |